ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2197

High Titer IgG Anti-Cyclic Citrullinated Peptide Antibodies Are Associated With Joint Destruction In Juvenile Idiopathic Arthritis Patients

Brooke Gilliam, Lance Feller and Terry L. Moore, Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

IgG anti-cyclic citrullinated peptide (anti-CCP) antibodies have been identified as an important indicator of destructive disease in juvenile idiopathic arthritis (JIA), as is the case in rheumatoid arthritis (RA). We evaluated sera from patients with three subtypes of JIA, in addition to RA patients and healthy individuals to investigate the significance of anti-CCP titers in relation to disease severity.

Methods:

Sera from 90 JIA patients were collected, including 30 IgM RF-positive polyarthritis, 30 IgM RF-negative polyarthritis, and 30 oligoarthritis. Sera were collected from 30 patients with RA and 30 healthy individuals. All sera were measured for IgG anti-CCP antibodies and IgM RF by ELISA. IgG anti-CCP antibody serum levels more than three times the cut-off (>60 Units) were considered high titer (HT) antibody levels. Patient records were evaluated for clinical and laboratory associations, including joint damage.

Results:

Fifteen IgM RF-positive polyarthritis patients had HT IgG anti-CCP antibodies, 5 had low titer (LT) anti-CCP antibodies, and 10 were considered negative. Two IgM RF-negative polyarthritis were positive for IgG anti-CCP antibodies, one with HT and one with LT. None of the oligoarthritis patients were positive for IgG anti-CCP antibodies, while 2 healthy children had LT IgG anti-CCP antibodies. Eighteen RA patients had HT IgG anti-CCP antibodies, one LT, and 11 were considered negative. IgM RF-positive polyarthritis patients demonstrated significantly elevated levels of IgG anti-CCP antibodies (85±80 Units) compared to IgM RF-negative polyarthritis (14±38 Units), oligoarthritis (5±5 Units), and healthy children (6±7 Units) (p<0.001). When IgM RF-positive polyarthritis levels were compared with levels in RA patients (102±85 Units), the difference was not significant (p=0.436). Nine of 16 (56.3%) JIA patients with HT IgG anti-CCP antibodies and 2/6 (33.3%) with LT IgG anti-CCP antibodies had joint damage. JIA patients with joint damage had significantly higher levels of IgG anti-CCP antibodies (83±84 Units) compared to those with no joint damage (23±49 Units) (p=0.008). Thirteen of 18 (72.2%) RA patients with HT, 1 LT, and 6/11 (54.5%) negative for IgG anti-CCP antibodies had joint damage. The difference in IgG anti-CCP antibody levels did not differ significantly in RA patients with or without joint damage (p=0.17). IgM RF levels were also significantly higher in JIA patients with joint damage (54±56 Units) compared to those with no joint damage (20±30 Units; p=0.026). Regression analysis showed that HT anti-CCP antibodies were the strongest independent determinant of joint damage in JIA (OR 8.13 [95% CI: 2.37-27.84], p=0.001). 

Conclusion:

IgM RF-positive polyarticular JIA and adult RA patients demonstrated similar mean levels of IgG anti-CCP antibodies, both greater than the HT cut-off of >60 Units. HT anti-CCP antibodies were strongly associated with joint damage in JIA. Measurement of IgG anti-CCP antibody serum levels was found to be useful in identifying JIA patients with destructive disease and would be useful in management of JIA, particularly patients with IgM RF-positive polyarthritis and overall in JIA patients exhibiting HTs.


Disclosure:

B. Gilliam,
None;

L. Feller,
None;

T. L. Moore,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-titer-igg-anti-cyclic-citrullinated-peptide-antibodies-are-associated-with-joint-destruction-in-juvenile-idiopathic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology